Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CERo Therapeutics Holdings, Inc. (CERO) SEC filings page on Stock Titan provides access to the company’s public reports and regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a clinical-stage biotechnology issuer and emerging growth company, CERo uses SEC filings to describe its immunotherapy platform, clinical programs, capital structure, and risk factors in detail.
Key filings for CERO include current reports on Form 8-K, which the company has used to announce material events such as Nasdaq listing determinations, private placements of Series E convertible preferred stock, equity line of credit agreements with institutional investors, and clinical or corporate presentations furnished under Regulation FD. These 8-Ks often provide timely information on financing terms, changes in trading venue, and progress of the CER-1236 program.
CERo’s registration statements on Form S-1 describe arrangements like its committed equity financing with an institutional investor, including the potential resale of large blocks of common stock issued under common stock purchase agreements. These documents outline how the company may raise capital over time and discuss associated risks and dilution considerations.
Other important disclosures include proxy materials on Schedule 14A, which have covered proposals such as a reverse stock split, increases to the 2024 Equity Incentive Plan share reserve, and approvals related to convertible preferred stock. Notifications like Form 12b-25 (NT 10-Q) explain delays in periodic reporting and provide preliminary financial information when applicable.
On this page, Stock Titan surfaces new CERO filings as they appear in the EDGAR system and applies AI to highlight key sections, such as clinical trial plans, financing covenants, listing status updates, and changes to capital structure. Users can quickly locate 10-K, 10-Q, S-1, 8-K, proxy statements, and other forms, while AI summaries help clarify technical language around preferred stock terms, equity lines, and regulatory or listing developments that may affect CERO shareholders.
CERO Therapeutics Holdings director Francois Eric received a stock option grant as equity compensation. The award covers options to buy 1,823,278 shares of Common Stock at an exercise price of $0.055 per share, held directly.
The options vest in full on the earlier of August 13, 2026 or the achievement of a specified clinical milestone in 2026, provided Eric remains in continuous service through the vesting date. The options expire on March 3, 2036, and following this grant he holds options for 1,823,278 underlying shares.
CERO THERAPEUTICS HOLDINGS, INC. director Francois Eric has filed a Form 3, which is an initial statement of beneficial ownership of the company’s securities. The filing establishes his status as a reporting person and does not list any purchase, sale, or other transaction activity.
CERo Therapeutics Holdings, Inc. registers 729,596,950 shares of Common Stock. This Prospectus Supplement No. 8 amends the Prospectus dated December 5, 2025 and attaches the Company’s Annual Report on Form 10-K filed April 15, 2026.
The supplement notes trading on OTCQB as “CERO” and OTCID warrants as “CEROW,” provides last quoted bid prices of $0.0320 per share (common stock) and $0.0035 per warrant as of April 14, 2026, and states that CERo is an emerging growth company. The Form 10-K discloses 36,786,686 shares outstanding as of April 14, 2026 and summarizes preclinical and Phase 1 clinical progress for lead candidate CER-1236, including FDA orphan and Fast Track designations and that five patients have been dosed in the ongoing Phase 1 AML study.
CERo Therapeutics Holdings, Inc. files its annual report describing progress on CER-1236, an autologous engineered T cell therapy targeting TIM-4 ligand for cancer. The company is running a first-in-human Phase 1/1b trial in acute myeloid leukemia, with five patients treated as of March 2026 and no dose-limiting toxicities reported to date.
CER-1236 has received FDA Orphan Drug Designation and Fast Track Designation for AML, and the trial has been expanded to include myelodysplastic syndrome and myelofibrosis. A separate Phase 1 study in non-small cell lung cancer and ovarian cancer is anticipated to begin in 2026. As of April 14, 2026, 36,786,686 shares of common stock were outstanding.
Cero Therapeutics Holdings, Inc. files Prospectus Supplement No. 7 to its Form S-1 registering 729,596,950 shares of common stock.
The supplement attaches a Form 8-K that discloses a convertible promissory note: a $350,000 purchase (principal face value $437,500) under a facility allowing borrowings up to $1,000,000, bearing interest at 10%, maturing April 9, 2027, and convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the prior 20 days, subject to a 4.99% beneficial ownership cap. The note requires registration of conversion shares on Form S-1 or S-3.
CERO Therapeutics Holdings, Inc. entered into a financing deal by issuing a convertible promissory note to Keystone Capital Partners for a purchase price of $350,000, with a principal face value of $437,500. Under this Note, the company may borrow up to an aggregate $1,000,000.
The Note bears 10% annual interest, matures on April 9, 2027, and can be converted into common stock at the lender’s option at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership cap.
The transaction was conducted as a private placement to an accredited investor under Section 4(a)(2) and Rule 506(b) of the Securities Act, and the company agreed to file a registration statement on Form S-1 or S-3 to cover resale of the conversion shares.
CERo Therapeutics Holdings, Inc. notified the SEC on Form 12b-25 that it could not timely file its Annual Report on Form 10-K for the year ended December 31, 2025 and expects to file within the fifteen calendar days allowed under Rule 12b-25. The company says it engaged a new independent auditor in February 2026, and the new auditor requires additional time to complete its review.
The filing discloses preliminary results as of March 31, 2026: an estimated net loss of $19.9 million for the year ended December 31, 2025 versus $8.3 million in the prior year, and $16.2 million of cash used in operating activities in 2025 versus $12.9 million in 2024. These figures are preliminary and subject to change in the completed Form 10-K.
CERO THERAPEUTICS HOLDINGS, INC. reports that Isaiah Tibbs beneficially owns 1,830,007 shares of Common Stock, representing 8.67% of the class. The filing states Tibbs has sole power to vote and sole dispositive power over all 1,830,007 shares.
CERO Therapeutics Holdings, Inc. registered 729,596,950 shares of Common Stock via a Prospectus Supplement. The supplement attaches a Form 8-K that discloses the issuance of a convertible promissory note with a purchase price of $750,000 (principal face value $937,500) and an available facility up to $1,000,000.
The Note bears interest at 10% per annum, matures on August 6, 2027, and is convertible at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the 20 trading days before a conversion request, subject to a 4.99% beneficial ownership limit. The Prospectus Supplement states a registration statement will cover resale of shares issuable upon conversion.
CERo Therapeutics Holdings, Inc. entered into a material definitive financing agreement by issuing and selling a convertible promissory note to Keystone Capital Partners, LLC for a purchase price of $750,000, with a principal face value of $937,500 and total borrowing capacity up to $1,000,000.
The note bears 10% annual interest, matures on August 6, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior twenty days, subject to a 4.99% beneficial ownership limit. The company must file a registration statement on Form S-1 or S-3 to cover resale of conversion shares, and the issuance relied on private offering exemptions under Sections 4(a)(2) and 3(a)(9) and Rule 506(b) of the Securities Act.